Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 12;7:70. doi: 10.1186/s40425-019-0538-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 2 — Associations of KIR3DL1 and its ligand status with clinical outcomes. Kaplan-Meier curves for TTRF (non-biological events censored) (a) and for duration of response (b) compare those treated with maintenance rituximab and KIR3DL1+/Bw4+ (Line 1: solid-black line), those treated with maintenance rituximab and not KIR3DL1+/Bw4+ (Line 2: dashed-black line), those treated with non-maintenance rituximab and KIR3DL1+/Bw4+ (Line 3: solid-red line) and those treated with non-maintenance rituximab and not KIR3DL1+/Bw4+ (Line 4: dashed-red line). c displays box-plots for percent tumor shrinkage for the four groups above (p-value not shown if p > 0.1). Outlying values are shown as filled circles outside the horizontal lines. (“*” indicates p < 0.05; “***” indicates p < 0.001)